AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34694215
Drug: Adapted smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted smoking cessation treatment
Trial: 35941622
Drug: Pulmonary rehabilitation
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary rehabilitation sessions (twice weekly for six weeks) consisting of supervised stretching, aerobic and strengthening exercises, and patient education.
Trial: 34397727
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 1.0 ng/mL
Trial: 34397727
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 2.0 ng/mL
Trial: 33284965
Drug: ω‐3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 supplementation (3 g/d)
Trial: 33026449
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus icotinib (125 mg 3 times a day)
Trial: 32740079
Drug: Low-volume same-day
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume same-day PEG (15 mg bisacodyl the day before, 2 L the morning of the procedure)
Trial: 32740079
Drug: Low-volume split-dose
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume split-dose PEG (15 mg bisacodyl the day before, 1 L + 1 L)
Trial: 32740079
Drug: Low-volume split-dose
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume split-dose PEG
Trial: 32740079
Drug: High-volume split-dose
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume split-dose PEG
Trial: 33607823
Drug: External application
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External application of mirabilite and rhubarb combined with intrathoracic chemotherapy (cisplatin)
Trial: 34532785
Drug: Programmed intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed intermittent epidural bolus (PIEB) 3 mL bolus every 60 min
Trial: 34532785
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (CEI) 3 mL/h
Trial: 32406659
Drug: Implant-supported fixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported fixed complete dentures
Trial: 34370166
Drug: Mobile health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile health educational intervention via WhatsApp messenger for 7 weeks on a daily schedule
Trial: 33999786
Drug: D/C/F/TAF 800/150/200/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D/C/F/TAF 800/150/200/10 mg
Trial: 35691295
Drug: FINLAY-FR-1A vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FINLAY-FR-1A vaccine (50 μg of recombinant dimeric receptor binding domain [RBD])
Trial: 35691295
Drug: FINLAY-FR-1A vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FINLAY-FR-1A vaccine
Trial: 35691295
Drug: Placebo (vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vaccine excipient)
Trial: 33023516
Drug: General beliefs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General beliefs about medication
Trial: 33067298
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus an enhanced rehabilitation programme (patient-held information workbook, goal setting diary, up to six additional therapy sessions)
Trial: 32785589
Drug: Imipenem/cilastatin/relebactam 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin/relebactam 500 mg/500 mg/250 mg
Trial: 32785589
Drug: Piperacillin/tazobactam 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam 4 g/500 mg
Trial: 36649072
Drug: Anti-PD-1 therapy
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 therapy
Trial: 33122393
Drug: MCSFA-HFD (diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCSFA-HFD (diet enriched with ∼30 g (5E%) saturated MCFAs)
Trial: 33843789
Drug: Intravenous estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous estrogen (25 mg)
Trial: 36356632
Drug: aprocitentan 12·5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aprocitentan 12·5 mg
Trial: 35686330
Drug: aprocitentan 25
RxNorm normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aprocitentan 25 mg
Trial: 33470031
Drug: 1.1 GBq
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1 GBq radioiodine therapy
Trial: 33470031
Drug: 3.7 GBq
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.7 GBq radioiodine therapy
Trial: 35927733
Drug: Weekly saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly saline (0.9%) washout in addition to standard LTC care
Trial: 35927733
Drug: Weekly citric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly citric acid (3.23%) washout in addition to standard LTC care
Trial: 34806783
Drug: Galcanezumab 300
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Galcanezumab 300 mg monthly for 12 weeks
Trial: 36145083
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of arginine and leucine supplementation and supervised adapted physical activity program (ALs+APA group, n = 20)
Trial: 33245150
Drug: Time Out
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Time Out consultation (TOC) before treatment decision
Trial: 32144927
Drug: Contralateral needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contralateral needling therapy
Trial: 35063278
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (200 mg daily alternating weeks) and Tamoxifen (20 mg twice daily)
Trial: 36241853
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg CBD
Trial: 35637624
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg CBD
Trial: 33021455
Drug: Flumazenil (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.05 mg/kg SC)
Trial: 34530886
Drug: Four-factor prothrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-factor prothrombin complex concentrate (PCC) 1 mL/kg (25 IU/ml of Factor IX/Kg) within 1-h post-admission
Trial: 34530886
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution 0.9% as a placebo
Trial: 33934982
Drug: Conventional oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oxygen therapy through a simple oxygen mask
Trial: 32560744
Drug: Candidate agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidate agents for COVID-19 treatment (specific candidates not detailed)
Trial: 35015750
Drug: Manual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual treatment maneuvers
Trial: 33181655
Drug: Comprehensive geriatric
RxNorm normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive geriatric assessment (CGA) and multi-disciplinary management including rehabilitation exercise, diet adjustment, multi-drug evaluation, acupoint massage in TCM, and patient education for 12 months
Trial: 35272599
Drug: COVID‐19 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID‐19 vaccine (CoronaVac)
Trial: 32585226
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration (10 L/min by face mask)
Trial: 35770251
Drug: QazCovid-in® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QazCovid-in® vaccine (5 μg each, 2 doses, 21 days apart)
Trial: 35770251
Drug: QazCovid-in® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QazCovid-in® vaccine
Trial: 32386922
Drug: First drug
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First drug administration
Trial: 34759559
Drug: Intraperitoneal nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal nebulization with 4 ml of 0.75% ropivacaine (Group B)
Trial: 34759559
Drug: Intraperitoneal nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal nebulization with 4 ml of saline (Group C)
Trial: 36333692
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (5000 units weekly for 3 months)
Trial: 33998243
Drug: Sacubitril/valsartan (S/V)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (S/V) treatment
Trial: 36106548
Drug: Restricted sacubitril/valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted sacubitril/valsartan (rS/V) treatment
Trial: 36106548
Drug: Conventional HF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional HF treatment (non-S/V)
Trial: 32976864
Drug: L-GrAFT7 risk
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-GrAFT7 risk score
Trial: 32976864
Drug: L-GrAFT7 risk
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-GrAFT7 risk score (highest tertile)
Trial: 32221696
Drug: NIC 18.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIC 18.7 mg/g
Trial: 32221696
Drug: NIC 10.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIC 10.8 mg/g
Trial: 32221696
Drug: NIC 5.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIC 5.3 mg/g
Trial: 32221696
Drug: NIC 2.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIC 2.3 mg/g
Trial: 32221696
Drug: NIC 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIC 1.3 mg/g
Trial: 32221696
Drug: NIC ≤
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NIC ≤ 2.3 mg/g
Trial: 32221696
Drug: NIC ≥
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NIC ≥ 5.3 mg/g
Trial: 35147131
Drug: Tripterygium wilfordii
RxNorm normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium wilfordii multiglycosides tablets (1-1.5 mg/kg body weight/d, orally) in addition to angiotensin converting enzyme inhibitor/angiotensin receptor blocker
Trial: 35147131
Drug: Angiotensin converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitor/angiotensin receptor blocker
Trial: 33328115
Drug: Gabby intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabby intervention (online conversational agent)
Trial: 32171422
Drug: Rifampicin 10
RxNorm normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extended release once daily for 8 weeks (RC8)
Trial: 32171422
Drug: Rifampicin 10
RxNorm normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 10 mg/kg plus intramuscular streptomycin 15 mg/kg once daily for 8 weeks (RS8)
Trial: 35324230
Drug: Web‐PE (Web‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web‐PE (Web‐based Prolonged Exposure Therapy)
Trial: 35324230
Drug: PCT (Present‐Centered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT (Present‐Centered Therapy)
Trial: 33121439
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence monitoring and quality of life assessments using validated self-reported instruments (EQ-5D-5L)
Trial: 36482599
Drug: Sublingual Immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual Immunotherapy with Dermatophagoides Farinae Drops for 3 months
Trial: 36482599
Drug: Mometasone Furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone Furoate nasal spray for 3 months
Trial: 36482599
Drug: Sublingual Immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual Immunotherapy
Trial: 36482599
Drug: Mometasone Furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone Furoate nasal spray
Trial: 34340637
Drug: Sequential combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential combination of aerobic exercise and computerized cognitive training (n = 20)
Trial: 35397826
Drug: Single session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single session treatment
Trial: 35397826
Drug: Weekly treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly treatment
Trial: 33894838
Drug: Cagrilintide 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cagrilintide 1.2 mg with semaglutide 2.4 mg
Trial: 33894838
Drug: Cagrilintide 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cagrilintide 2.4 mg with semaglutide 2.4 mg
Trial: 33894838
Drug: Cagrilintide 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cagrilintide 4.5 mg with semaglutide 2.4 mg
Trial: 33894838
Drug: Cagrilintide (0.16–4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cagrilintide (0.16–4.5 mg) and semaglutide 2.4 mg
Trial: 34353065
Drug: Floating needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floating needle therapy combined with acupoint embedding
Trial: 32685097
Drug: Mulberry milk
RxNorm normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mulberry milk (10 g)
Trial: 32685097
Drug: Placebo milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo milk (50 mL)
Trial: 35191639
Drug: Bilateral lumbar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral lumbar ultrasound-guided erector spinae plane block (ESPB) with 0.375% ropivacaine 40 mL
Trial: 35191639
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration with 0.375% ropivacaine 40 mL
Trial: 33710764
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy (combination therapy group)
Trial: 33710764
Drug: Pembrolizumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab monotherapy (monotherapy group)
Trial: 33710764
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with PD-L1 TPS ≥50% in combination therapy group
Trial: 33710764
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with PD-L1 TPS ≥50% in monotherapy group
Trial: 36148625
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) powder
Trial: 33762145
Drug: High-dose coaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose coaching with ECHO
Trial: 33762145
Drug: High-dose coaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose coaching without ECHO
Trial: 33762145
Drug: Low-dose coaching
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose coaching with ECHO
Trial: 33762145
Drug: Low-dose coaching
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose coaching without ECHO
Trial: 33557035
Drug: CE+HCO3 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE+HCO3 group (carbohydrate-electrolyte solution with bicarbonate)
Trial: 35455245
Drug: MF59-adjuvanted, H5N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted, H5N1 influenza pandemic vaccine (aH5N1c), two doses administered 21 days apart
Trial: 35455245
Drug: MF59-adjuvanted, H5N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted, H5N1 influenza pandemic vaccine (aH5N1c)
Trial: 36158118
Drug: Improved oral
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved oral care method (oral scrubbing before intubation, brushing and washing after intubation, 3 times per day, using 0.1% povidone-iodine in oral care solution)
Trial: 36158118
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral care (scrubbing 3 times per day, using physiological brine)
Trial: 36158118
Drug: Improved oral
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved oral care method
Trial: 33732655
Drug: Maternal antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal antibiotic usage
Trial: 36052499
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and common medication
Trial: 36052499
Drug: Common medication
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common medication only
Trial: 32338445
Drug: HOPE service
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOPE service (brief psychological therapy)
Trial: 33277507
Drug: tiotropium/olodaterol (5/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium/olodaterol (5/5 µg) via Respimat® inhaler
Trial: 35189093
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg vaginal progesterone suppository nightly from 16 to 36 weeks of gestation
Trial: 35189093
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg intramuscular 17-hydroxyprogesterone caproate weekly from 16 to 36 weeks of gestation
Trial: 35189093
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg vaginal progesterone suppository nightly
Trial: 35189093
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg intramuscular 17-hydroxyprogesterone caproate weekly
Trial: 32701012
Drug: OBG 8
RxNorm normalized name: OBGYN Procedure Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBG 8 times daily for 3 days, followed by 4 times daily for 11 days (Group 1)
Trial: 32701012
Drug: OBG 4
RxNorm normalized name: OBGYN Procedure Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBG 4 times daily for 14 days (Group 2)
Trial: 35257461
Drug: iGlarLixi (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iGlarLixi (insulin glargine 100 U/ml + lixisenatide)
Trial: 94240848
Drug: Sclerotherapy in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclerotherapy in combination with enalapril
Trial: 36222207
Drug: Bromocriptine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (7.5 mg daily) in group 1 (early-onset androgenic alopecia)
Trial: 36222207
Drug: Bromocriptine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (7.5 mg daily) in group 2 (normal hair growth)
Trial: 34338111
Drug: Non-selective beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective beta-blockers (n = 113)
Trial: 34338111
Drug: Non-selective beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective beta-blockers (n = 40)
Trial: 34338111
Drug: Selective beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective beta-blockers and metformin
Trial: 33164945
Drug: 24-hour infusion
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour infusion of levodopa/carbidopa (720/90 mg)
Trial: 33164945
Drug: 14-hour 'waking-day'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-hour 'waking-day' infusion of levodopa/carbidopa (538/68 mg plus a morning oral dose of 150/15 mg)
Trial: 32451212
Drug: Trivalent live
RxNorm normalized name: influenza vaccine trivalent live 2024-2025 (2 yrs-49 yrs) 10exp6.5-7.5 FF unit/0.2 mL NASAL NASAL SPRAY SYRINGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent live human-lamb reassortant rotavirus vaccine (LLR3)
Trial: 35151280
Drug: Mictalase® suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mictalase® suppositories (Phenolmicin P3 and Bosexil) administered twice a day for 5 days, then once a day for 10 days